Why MPLT Stock slipped -1.81% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, MPLT scores 35 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -32.4%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and institutional flow, which together indicate that the reported losses and negative free cash flow are not yet offset by a demonstrated earnings path or sponsorship from large holders. The forensic balance sheet pillar is the strongest of the five but still sits at half its maximum, reflecting a Piotroski F-Score of 2 out of 9. The Beta of 1.0 means the stock is rated as moving in line with the broader market, so macro regime fit does little to differentiate it. Any upside case would rest on catalysts rather than on current cash generation, and the balance of evidence in this rating points toward elevated risk to the equity relative to its reported fundamentals.

Per the SEC financials, operating and net losses widened from FY 2024 to FY 2025, and free cash flow was negative in both periods. Gross, operating, and net margins are each reported as 0% in the market data. Per the Roarable RQD rating, ROIC is -32.4% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 2 out of 9 and Debt/Equity is 0.5. Cash rose from $38.3M to $46.7M over the period, but the source data does not establish the funding sources behind that change.

Per the recent news feed, the items are as follows:

• A MarketBeat report (YELLOW) on analyst views of the stock.
• A TradingView estimates report (YELLOW) and a Seeking Alpha item (YELLOW) reporting that a MapLight co-founder is a joint winner of the 2026 Nobel Prize in Medicine.
• A Stock Titan item (YELLOW) reporting that an officer proposes selling 15,355 shares solely for vesting taxes.
• A MarketBeat item flagged RED under RISK WATCH reporting a 5.5% stock decline.
• A MarketBeat item (YELLOW) reporting the stock reached a new 52-week low.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The only RED-flagged item is the decline report, and the 52-week low report is consistent with the market data range of $7.44 - $40.43.

• What are the company's products, pipeline stage, and revenue model, given that reported revenue is $0.0M in both periods?
• How does the FY 2025 cash balance of $46.7M compare with the $-138.6M free cash flow burn, and what financing sources or timelines apply?
• What is the amount and terms of any debt, since the Debt field is N/A for both periods despite a Debt/Equity ratio of 0.5?
• What is the company's EPS, P/E, and EV/EBITDA, which are all unavailable in the source data?
• What is the institutional and insider ownership profile, given that holders data is NONE?